CR represents an early index of potential long survival in multiple myeloma

Bone Marrow Transplantation

Volumn 45, Issue 3, 2010, Pages 498-504

  Wang, M ^a   Delasalle, K ^a   Feng, L ^a   Thomas, S ^a   Giralt, S ^a   Qazilbash, M ^a   Handy, B ^a   Lee, J J ^a   Alexanian, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Auto SCT; Complete response; Multiple myeloma; Prognostic factors

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; INTERFERON; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949424100     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.176     Document Type: Article

References (26)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
2. Child J, Morgan G, Davies F, Owen R, Bell S, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
3. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-89.
4. Alexanian R, Dimopoulos M, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-890.
5. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
6. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.
7. Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt S. Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant 2004; 34: 229-234.
8. Greipp PR, San Miguel J, Durie BG, Crowly J, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
9. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
10. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
11. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Rep 1966; 50: 163-170.
12. Anderson J, Cain K, Gelber R. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719.
13. Cox D. Regression models and life tables. J Royal Stat Soc 1972; 34: 187-220.
14. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
15. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55-65 years: long-term results of a randomized control trail from the Group Myeloma- Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
16. Vesole D, Crowley S, Catchatourian R, Stiff P, Johnson D, Cromer J et al. High-dose melphalan with autotransplantation for refractory multiple myeloma. J Clin Oncol 1999; 17: 2173-2179.
17. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679.
18. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar S, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Haematologica 2004; 34: 161-167.
19. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet J et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
20. Dingli D, Pacheco J, Nowakowski G, Kumar S, Dispenzieri A, Hayman S et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933-4937.
21. Kim J, Kim K, Cheong J, Min Y, Suh C, Kim H et al. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Biol Blood Marrow Transplant 2009; 15: 463-470.
22. Lahuerta J, Mateos M, Martinez-Lopez J, Rosiñol L, Sureda A, de la Rubia J et al. Influence of pre- and posttransplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782.
23. Kumar S, Dingli D, Dispenzieri A, Lacy M, Hayman S, Buadi F et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant 2008; 42: 259-264.
24. Durie B, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcomes. J Clin Oncol 2004; 22: 1857-1863.
25. Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained for 3 years from treatment initiation is a powerful surrogate marker for extended survival in multiple myeloma. Cancer 2008; 113: 355-359.
26. Barlogie B, Tricot G, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haemat 2006; 135: 158-164.